JP2022504217A5 - - Google Patents
Info
- Publication number
- JP2022504217A5 JP2022504217A5 JP2021518527A JP2021518527A JP2022504217A5 JP 2022504217 A5 JP2022504217 A5 JP 2022504217A5 JP 2021518527 A JP2021518527 A JP 2021518527A JP 2021518527 A JP2021518527 A JP 2021518527A JP 2022504217 A5 JP2022504217 A5 JP 2022504217A5
- Authority
- JP
- Japan
- Prior art keywords
- recombinant polypeptide
- polypeptide according
- seq
- item
- mog
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862741941P | 2018-10-05 | 2018-10-05 | |
| US62/741,941 | 2018-10-05 | ||
| PCT/US2019/054850 WO2020072992A1 (en) | 2018-10-05 | 2019-10-04 | Recombinant polypeptides comprising modified mhc class ii drα1 domains and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022504217A JP2022504217A (ja) | 2022-01-13 |
| JP2022504217A5 true JP2022504217A5 (https=) | 2022-10-13 |
| JP7511551B2 JP7511551B2 (ja) | 2024-07-05 |
Family
ID=68296863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021518527A Active JP7511551B2 (ja) | 2018-10-05 | 2019-10-04 | 改変されたＭＨＣクラスＩＩ ＤＲα１ドメインを含む組換えポリペプチドおよび使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11945855B2 (https=) |
| EP (1) | EP3860644A1 (https=) |
| JP (1) | JP7511551B2 (https=) |
| KR (1) | KR102925681B1 (https=) |
| CN (1) | CN113164573B (https=) |
| AU (1) | AU2019355062B2 (https=) |
| CA (1) | CA3114446A1 (https=) |
| WO (1) | WO2020072992A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4719466A1 (en) * | 2023-05-26 | 2026-04-08 | Oregon Health & Science University | Treatment of cancer with drq polypeptides |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5468481A (en) | 1988-06-23 | 1995-11-21 | Amergen, Inc. | MHC class II-peptide conjugates useful in ameliorating autoimmunity |
| US8377447B2 (en) | 2003-09-05 | 2013-02-19 | Oregon Health & Science University | Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells |
| EP2655624B1 (en) | 2010-12-23 | 2017-11-29 | Biogen MA Inc. | Linker peptides and polypeptides comprising same |
| US20130309229A1 (en) | 2011-01-28 | 2013-11-21 | The United States Government As Represented By The Department Of Veterans Affairs | Recombinant t cell ligands and antibodies that bind b cells for the treatment of autoimmune diseases |
| US9260506B2 (en) | 2011-04-07 | 2016-02-16 | Oregon Health & Science University | Treatment of retinal disorders with recombinant T cell receptor ligand (RTL) |
| JP6364352B2 (ja) | 2012-01-06 | 2018-07-25 | オレゴン ヘルス アンド サイエンス ユニバーシティ | 部分的ｍｈｃコンストラクト及びその使用方法 |
| WO2015051328A1 (en) | 2013-10-03 | 2015-04-09 | Oregon Health & Science University | TREATMENT OF ISCHEMIC STROKE WITH DRα1-MOG-35-55 |
| EP3052526A4 (en) | 2013-10-03 | 2017-04-19 | Oregon Health & Science University | Recombinant polypeptides comprising mhc class ii 1 domains |
| WO2017070569A1 (en) | 2015-10-23 | 2017-04-27 | Oregon Health & Science University | Compounds that bind macrophage migration inhibitory factor |
| US10689446B2 (en) | 2016-06-22 | 2020-06-23 | Oregon Health & Science University | Recombinant CD74 polypeptides |
| US20180127481A1 (en) * | 2016-11-09 | 2018-05-10 | Uti Limited Partnership | RECOMBINANT pMHC CLASS II MOLECULES |
| US20180271935A1 (en) | 2017-03-15 | 2018-09-27 | Oregon Health & Science University | Dralpha1-mog-35-55 treatment of traumatic brain injury |
-
2019
- 2019-10-04 US US17/282,455 patent/US11945855B2/en active Active
- 2019-10-04 CA CA3114446A patent/CA3114446A1/en active Pending
- 2019-10-04 CN CN201980079085.8A patent/CN113164573B/zh active Active
- 2019-10-04 AU AU2019355062A patent/AU2019355062B2/en active Active
- 2019-10-04 WO PCT/US2019/054850 patent/WO2020072992A1/en not_active Ceased
- 2019-10-04 KR KR1020217012762A patent/KR102925681B1/ko active Active
- 2019-10-04 JP JP2021518527A patent/JP7511551B2/ja active Active
- 2019-10-04 EP EP19791143.1A patent/EP3860644A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023504914A5 (https=) | ||
| JP2016529229A5 (https=) | ||
| JP2023544834A5 (https=) | ||
| JP2017527272A5 (https=) | ||
| CN111542343A (zh) | 抗bcma的单域抗体及其应用 | |
| MX389173B (es) | Receptores de celulas t. | |
| JP2022502371A5 (https=) | ||
| JP2013513377A5 (https=) | ||
| JP2015509097A5 (https=) | ||
| JP2018522563A5 (https=) | ||
| JP2018537087A5 (https=) | ||
| AR086360A1 (es) | Polipeptidos anticuerpos que antagonizan cd40 | |
| JP2017018125A5 (https=) | ||
| JP2017515470A5 (https=) | ||
| JP2020501550A5 (https=) | ||
| JP2017500018A5 (https=) | ||
| JP2023505492A5 (https=) | ||
| JP2018509935A5 (https=) | ||
| JP2017514522A5 (https=) | ||
| JP2017512063A5 (https=) | ||
| MX2009004665A (es) | Anticuerpos de anti-factor d humanizado. | |
| JP2016538885A5 (https=) | ||
| HRP20151227T1 (hr) | Sastavi i postupci uporabe za terapeutska protutijela | |
| NZ591130A (en) | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof | |
| JP2023528207A5 (https=) |